Telix Pharmaceuticals Ltd (STU:T3X)
€ 14.8 0.49 (3.42%) Market Cap: 4.90 Bil Enterprise Value: 4.84 Bil PE Ratio: 162.08 PB Ratio: 19.98 GF Score: 75/100

Half Year 2024 Telix Pharmaceuticals Ltd Earnings Call Transcript

Aug 22, 2024 / 11:00PM GMT
Release Date Price: €12.19 (+1.50%)
Kyahn Williamson
Telix Pharmaceuticals Ltd - Senior Vice President of Investor Relations and Corporate Communications

Thank you. And thank you, everybody, for joining us today. We can just skip through our disclaimer slide there for (inaudible).

If we go to slide 3, I just want to briefly introduce the agenda and the people on the call today. So we'll be taking you through the introduction and the results summary, our achievements for H1 2024, detailed financial commentary and outlook. So on the call, I'm joined by Dr. Chris Behrenbruch, our Managing Director and Group Chief Executive Officer; Darren Smith, our Group Chief Financial Officer; and David Cade, our Group Chief Medical Officer.

We can turn to slide 4. Obviously, the purpose of today's briefing is to take you through our half year financial results and the detailed commentary, but also the operational achievements for the period. Once again, it's been a period of really high activity and progress across our commercial, clinical research, and manufacturing programs. And I think whenever I speak to investors, I always get the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot